Drug Discovery World
APRIL 29, 2024
Hall has been with the company for more than 16 years, including as Chief Commercial Officer, and was previously Head of Business Development in Europe for Cyprotex. Bironneau brings over two decades of commercial leadership experience, including as Vice President, Global Sales & Business Development at Axplora and Novasep.
The Pharma Data
JUNE 7, 2023
Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 30, 2023
Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. This was followed by another presentation in the track, within the session on harnessing neutrophils using bispecifics.
pharmaphorum
MARCH 8, 2022
After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. Avideh Nazeri is vice president clinical development, medical, and regulatory affairs, Novo Nordisk UK.
Drug Discovery World
JUNE 5, 2023
New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. The discussion answered three main questions: What is the new direction for the company?
The Pharma Data
JUNE 28, 2021
“Despite increased cancer survivorship overall, there continues to be significant unmet need in oncology,” said Marianne De Backer, MBA, PhD, Member of the Executive Committee of the Pharmaceuticals Division and Head Strategy and Business Development & Licensing at Bayer. “We
Drug Discovery World
MAY 16, 2023
According to Foster, the industry needs to work together to address the problems from the earliest phases of pre-clinical development. Clinical endpoints are no longer the only things that matter. Allogeneic cell therapy is also starting to accelerate in early development programs. The solution?
Expert insights. Personalized for you.
52 
Let's personalize your content